Cargando…

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Neeta, Padron, Elizabeth Jordan, Rammohan, Kottil W., Goodman, Courtney Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604914/
https://www.ncbi.nlm.nih.gov/pubmed/36294458
http://dx.doi.org/10.3390/jcm11206139
_version_ 1784817934947844096
author Garg, Neeta
Padron, Elizabeth Jordan
Rammohan, Kottil W.
Goodman, Courtney Frances
author_facet Garg, Neeta
Padron, Elizabeth Jordan
Rammohan, Kottil W.
Goodman, Courtney Frances
author_sort Garg, Neeta
collection PubMed
description Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders.
format Online
Article
Text
id pubmed-9604914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96049142022-10-27 Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis Garg, Neeta Padron, Elizabeth Jordan Rammohan, Kottil W. Goodman, Courtney Frances J Clin Med Review Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders. MDPI 2022-10-18 /pmc/articles/PMC9604914/ /pubmed/36294458 http://dx.doi.org/10.3390/jcm11206139 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Garg, Neeta
Padron, Elizabeth Jordan
Rammohan, Kottil W.
Goodman, Courtney Frances
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title_full Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title_fullStr Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title_full_unstemmed Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title_short Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
title_sort bruton’s tyrosine kinase inhibitors: the next frontier of b-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604914/
https://www.ncbi.nlm.nih.gov/pubmed/36294458
http://dx.doi.org/10.3390/jcm11206139
work_keys_str_mv AT gargneeta brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis
AT padronelizabethjordan brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis
AT rammohankottilw brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis
AT goodmancourtneyfrances brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis